Idexx laboratories announces fourth quarter and full year 2021 results

Westbrook, maine, feb. 2, 2022 /prnewswire/ -- achieves 11% fourth quarter revenue growth as reported and 10.5% organic, driven by 13% cag diagnostics recurring revenue growth (reported and organic) strong growth supported by record instrument placements, resulting in 14% year-over-year expansion of idexx's global premium instrument installed base delivers full year eps of $8.60, an increase of 28% on a reported basis and 29% on a comparable basis, supported by operating margin expansion of 330 basis points as reported and 220 basis points on a comparable basis provides initial outlook for 2022 revenue of $3,500 million - $3,565 million, reflecting reported growth of 9% - 11% and organic growth of 10% - 12% estimates 2022 eps of $9.27 - $9.59, an increase of 8% - 11% as reported and 12% - 16% on a comparable basis, including an estimated $0.15 per share or ~2% eps growth impact from higher projected international tax rates idexx laboratories, inc. (nasdaq: idxx), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced fourth quarter and full year results, as well as an update on u.s. companion animal diagnostic trends. fourth quarter and full year results the company reports revenues of $801 million for the fourth quarter of 2021, an increase of 11% compared to the prior year period on a reported basis and 10.5% on an organic basis.
IDXX Ratings Summary
IDXX Quant Ranking